A comparison of in vitro bioassays to determine cellular glucocorticoid sensitivity

European Journal of Endocrinology

Volumn 150, Issue 1, 2004, Pages 41-47

  Vermeer, H ^a   Hendriks Stegeman, B I ^a   Verrijn Stuart, A A ^a   van Buul Offers, S C ^a   Jansen, M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FK 506 BINDING PROTEIN; GLUCOCORTICOID; MESSENGER RNA; MITOGENIC AGENT;

ADULT; ARTICLE; ASTHMA; BIOASSAY; CELL ISOLATION; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG RESISTANCE; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERMETHOD COMPARISON; MALE; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN INDUCTION; REPRODUCIBILITY; RHEUMATOID ARTHRITIS;

ADULT; BIOLOGICAL ASSAY; CELL DIVISION; DEXAMETHASONE; DRUG HYPERSENSITIVITY; FEMALE; GENE EXPRESSION; GLUCOCORTICOIDS; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; RNA, MESSENGER; TACROLIMUS BINDING PROTEINS;

EID: 0742289428     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1500041     Document Type: Article

References (28)

1. Grebe SK, Feek CM, Durham JA, Kljakovic M & Cooke RR. Inhaled beclomethasone dipropionate suppresses the hypothalamo-pituitary-adrenal axis in a dose dependent manner. Clinical Endocrinology 1997 47 297-304.
2. Nishimura J & Ikuyama S. Glucocorticoid-induced osteoporosis: pathogenesis and management. Journal of Bone and Mineral Metabolism 2000 18 350-352.
3. Slater JHD, Heffron PF, Vernet A & Nabarro JDN. Clinical and metabolic effects of dexamethasone. Lancet 1959 1 173-177.
4. Harrison TW, Wisniewski A, Honour J & Tattersfield AE. Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects. Thorax 2001 56 186-191.
5. Umland SP, Schleimer RP & Johnston SL. Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma. Pulmonary Pharmacology and Therapeutics 2002 15 35-50.
6. Zimmerman B, Gold M, Wherrett D & Hanna AK. Adrenal suppression in two patients with asthma treated with low doses of the inhaled steroid fluticasone propionate. Journal of Allergy and Clinical Immunology 1998 101 425-426.
7. Lamberts SW, Huizenga NA, de Lange P, de Jong FH & Koper JW. Clinical aspects of glucocorticoid sensitivity. Steroids 1996 61 157-160.
8. Kino T & Chrousos GP. Glucocorticoid and mineralocorticoid resistance/hypersensitivity syndromes. Journal of Endocrinology 2001 169 437-445.
9. Raivio T, Palvimo JJ, Kannisto S, Voutilainen R & Jänne OA. Transactivation assay for determination of glucocorticoid bioactivity in human serum. Journal of Clinical Endocrinology and Metabolism 2002 87 3740-3744.
10. Vermeer H, Hendriks-Stegeman BI, Van den Brink CE, Van der Saag PT, Van der Burg B, Van Buul-Offers SC et al. A novel specific bioassay for the determination of glucocorticoid bioavailability in human serum. Clinical Endocrinology 2003 59 49-55.
11. Hearing SD, Norman M, Smyth C, Foy C & Dayan CM. Wide variation in lymphocyte steroid sensitivity among healthy human volunteers. Journal of Clinical Endocrinology and Metabolism 1999 84 4149-4154.
12. Spahn JD, Landwehr LP, Nimmagadda S, Surs W, Leung DY & Szefler SJ. Effects of glucocorticoids on lymphocyte activation in patients with steroid-sensitive and steroid-resistant asthma. Journal of Allergy and Clinical Immunology 1996 98 1073-1079.
13. Huizenga NA, de Lange P, Koper JW, De Herder WW, Abs R, Kasteren JHLMV et al. Five patients with biochemical and/or clinical generalized glucocorticoid resistance without alterations in the glucocorticoid receptor gene. Journal of Clinical Endocrinology and Metabolism 2000 85 2076-2081.
14. Lamberts SW, Koper JW, Biemond P, Den Holder FH & de Jong FH. Cortisol receptor resistance: the variability of its clinical presentation and response to treatment. Journal of Clinical Endocrinology and Metabolism 1992 74 313-321.
15. Kavelaars A, Kuis W, Knook L, Sinnema G & Heijnen CJ. Disturbed neuroendocrine-immune interactions in chronic fatigue syndrome. Journal of Clinical Endocrinology and Metabolism 2000 85 692-696.
16. Hearing SD, Norman M & Dayan CM. In vitro measurement of lymphocyte steroid sensitivity: lack of agreement between whole blood culture and separated lymphocyte culture. Immunopharmacology and Immunotoxicology 1999 21 41-53.
17. Van Reijen EAM, Harvey RA, Barton RN, Rose JG & Horan MA. Sensitivity of mononuclear leucocytes to glucocorticoids in elderly hip-fracture patients resistant to suppression of plasma cortisol by dexamethasone. European Journal of Endocrinology 1998 138 659-666.
18. Fan J, Nishanain P, Breen EC, McDonald M & Fahey JL. Cytokine gone expression in normal human lymphocytes in response to stimulation. Clinical and Diagnostic Laboratory Immunology 1998 5 335-340.
19. Chen H-J, Hwong C-L, Wang C-H & Hwan J. Degradation of DNA topoisomerase I by a novel trypsin-like serine protease in proliferating human T lymphocytes. Journal of Biological Chemistry 2000 275 13109-13117.
20. Reguzzoni M, Cosentino M, Rasini E, Marino F, Ferrari M, Bombelli R et al. Ultrastructural localization of tyrosine hydroxylase in human peripheral blood mononuclear cells: effect of stimulation with phytohaemagglutinin. Cell and Tissue Research 2002 310 297-304.
21. Baughman G, Wiederrecht GJ, Campbell NF, Martin MM & Bourgeois S. FKBP51, a novel T-cell-specific immunophilin capable of calcineurin inhibition. Molecular and Cellular Biology 1995 15 4395-4402.
22. Vermeer H, Hendriks-Stegeman BI, Van der Burg B, Van Buul-Offers SC & Jansen M. Glucocorticoid-induced increase in lymphocytic FKBP51 mRNA expression: a potential marker for glucocorticoid sensitivity, potency and bioavailability. Journal of Clinical Endocrinology and Metabolism 2003 88 277-284.
23. Karl M, Lamberts SW, Detera-Wadleigh SD, Encio IJ, Stratakis CA, Hurley DM et al. Familial glucocorticoid resistance caused by a splice site deletion in the human glucocorticoid receptor gene. Journal of Clinical Endocrinology and Metabolism 1993 76 683-689.
24. Tay DL, Hoffbrand AV & Wickremasinghe GR. Expression of c-fos and c-jun proteins and AP-1 binding activity during cell cycle progression of HL60 cells and phytohemagglutinin-stimulated lymphocytes. Experimental Hematology 1996 24 277-284.
25. Herrlich P. Cross-talk between glucocorticoid receptor and AP-1. Oncogene 2001 20 2465-2475.
26. Jonat C, Rahmsdorf HJ, Park K-K, Cato ACB, Gebel S, Ponta H et al. Novel glucocorticoid receptor coactivator effector mechanisms. Cell 1990 62 1189-1204.
27. Kraft M, Vianna E, Martin RJ & Leung DM. Nocturnal asthma is associated with reduced glucocorticoid receptor binding affinity and decreased steroid responsiveness at night. Journal of Allergy and Clinical Immunology 1999 103 66-71.
28. Wei T, Knight RA & Lightman S. Mitogenic response and steroid sensitivity in MS lymphocytes. Acta Neurologica Scandinavia 1997 96 28-33.